• The Trump administration granted a contract worth up to $812 million to a small Virginia firm to boost the US’s production of pharmaceuticals.
  • The firm, Phlow, was founded in January and describes itself as a “public benefit pharmaceutical manufacturing company.”
  • Its CEO, Dr. Eric Edwards, told The Associated Press that Phlow’s mission is to make the US’s drug supply chain less reliant on other countries — something the Trump administration said has been made more urgent by the coronavirus pandemic.
  • According to STAT News, Edwards has a checkered history in the pharmaceutical industry.
  • Peter Navarro, the White House trade adviser, told The Wall Street Journal he had bonded with a Phlow board member over his China skepticism after she read his book.
  • Visit Business Insider’s homepage for more stories.

The Trump administration handed a contract worth up to $812 million to a small Virginia firm to boost the US’s production of coronavirus drugs and reduce reliance on foreign pharmaceutical supply chains.

The firm, Phlow, was founded in January and describes itself as a “public benefit pharmaceutical manufacturing company.” The contract is a huge sum for such a new firm.

The Department of Health and Human Services said on Tuesday that its Biomedical Advanced Research and Development Authority, which directs federal money to companies countering public-health threats, was giving the contract to Phlow.

The company aims to manufacture raw ingredients in the US for drugs needed to treat COVID-19 patients, CBS News reported.

According to The New York Times, US companies already produce the same drugs, but they rely on foreign raw ingredients that Phlow aims to

Read More